Overview
Background
Professor Gabrielli completed his undergraduate education at James Cook University in Townsville and PhD at La Trobe University in Melbourne. After two postdoctoral positions in the USA in the emerging field of cell cycle regulation, he was recruited to establish his own independent research at the Queensland Institute of Medical Research, and then recruited to the Diamantina Institute in 2002, and Mater Research Institute in 2016. He is head of the Smiling for Smiddy Cell Cycle Group.
Research Interests
Mechanisms that regulate cell division, particularly progression into mitosis. These mechanisms are often mutated in cancers and are likely to be major contributors to cancer development. Identifying the genetic mutations that disrupt normal progression and particularly mechanisms, known as checkpoints, provides diagnostic and prognostic opportunities. It also provides potential new targets for chemotherapeutics as drugs targeting defective checkpoints have tumour selective cytotoxic potential.
Research Projects
- Identifying the molecular basis for defective checkpoints in melanoma.
- Targeting defective cell cycle responses to ultraviolet radiation, replication stress and TopoII inhibitors in melanoma, and investigating whether the same defects in other cancer types respond to similar targeting.
- Investigating means of identify very early changes in moles that drive progression to melanoma
- Targeting Aurora kinases in HPV-driven cancers
Availability
- Professor Brian Gabrielli is:
- Available for supervision
- Media expert
Fields of research
Qualifications
- Bachelor (Honours) of Science (Advanced), James Cook University
- Doctor of Philosophy, La Trobe University
Research interests
-
Ultraviolet radiaiton and its contribution to melanoma
-
Targeting defective cell cycle checkpoints in cancers, particularly melanoma
-
Functional genomics; using high throughout screening combined with increased or decreased gene dosage to identify novel regulatory mechanisms and drug targets
-
Mechanism of action studies for novel anti-caner therapeutics
Works
Search Professor Brian Gabrielli’s works on UQ eSpace
2018
Journal Article
Mechanism of action of the third generation benzopyrans and evaluation of their broad anti-cancer activity in vitro and in vivo
Stevenson, Alexander J., Ager, Eleanor I., Proctor, Martina A., Škalamera, Dubravka, Heaton, Andrew, Brown, David and Gabrielli, Brian G. (2018). Mechanism of action of the third generation benzopyrans and evaluation of their broad anti-cancer activity in vitro and in vivo. Scientific Reports, 8 (1) 22882, 5144. doi: 10.1038/s41598-018-22882-w
2018
Journal Article
Discovery of thalicthuberine as a novel antimitotic agent from nature that disrupts microtubule dynamics and induces apoptosis in prostate cancer cells
Levrier, Claire, Rockstroh, Anja, Gabrielli, Brian, Kavallaris, Maria, Lehman, Melanie, Davis, Rohan A, Sadowski, Martin C and Nelson, Colleen C (2018). Discovery of thalicthuberine as a novel antimitotic agent from nature that disrupts microtubule dynamics and induces apoptosis in prostate cancer cells. Cell Cycle, 17 (5), 652-668. doi: 10.1080/15384101.2017.1356512
2018
Journal Article
Acetylsalicylic acid governs the effect of sorafenib in RAS- mutant cancers
Hammerlindl, Heinz, Ravindran Menon, Dinoop, Hammerlindl, Sabrina, Emran, Abdullah Al, Torrano, Joachim, Sproesser, Katrin, Thakkar, Divya, Xiao, Min, Atkinson, Victoria G., Gabrielli, Brian, Haass, Nikolas K., Herlyn, Meenhard, Krepler, Clemens and Schaider, Helmut (2018). Acetylsalicylic acid governs the effect of sorafenib in RAS- mutant cancers. Clinical Cancer Research, 24 (5), 1090-1102. doi: 10.1158/1078-0432.CCR-16-2118
2018
Conference Publication
Distinct epigenetic remodelling defines early stress-induced drug tolerance in melanoma
Emran, A., Marzese, D. M., Menon, D. R., Stark, M., Torrano, J., Hammerlindl, H., Zhang, G., Brafford, P., Hammerlindl, S., Gupta, D., Mills, G. B., Lu, Y., Flaherty, K., Sturm, R., Hoon, D. S. B., Gabrielli, B., Herlyn, M. and Schaider, H. (2018). Distinct epigenetic remodelling defines early stress-induced drug tolerance in melanoma. Australasian College of Dermatologists, 51st Annual Scientific Meeting, Gold Coast, QLD, Australia , 19–22 May 2018. Richmond, VIC, Australia: Wiley-Blackwell Publishing. doi: 10.1111/ajd.16_12815
2018
Conference Publication
Targeting cell cycle phase-specific drug sensitivity for melanoma therapy
Daignault, S. M., Hill, D. S., Spoerri, L., Stehbens, S., Weninger, W., Gabrielli, B., Dolcetti, R. and Haass, N. K. (2018). Targeting cell cycle phase-specific drug sensitivity for melanoma therapy. 45th Annual Meeting of the Arbeitsgemeinscha-Dermatologische-Forschung (ADF), Zurich, Switzerland, 7-10 March 2018. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing.
2018
Conference Publication
Overexpression of the cell cycle regulator Emi1 promotes chromosome instability and tumorigenesis
Duijf, Pascal H. G., Vaidyanathan, Srividya, Cato, Kathleen, Thangavelu, Pulari U., Lin, Cheng-Yu, Tang, Lu, Pavey, Sandra, Haass, Nikolas K. and Gabrielli, Brian G. (2018). Overexpression of the cell cycle regulator Emi1 promotes chromosome instability and tumorigenesis. 76th Annual Meeting of the Japanese Cancer Association, Yokohama, Japan, 28-30 September 2017. Tokyo, Japan: Wiley Japan. doi: 10.1111/cas.13499
2017
Journal Article
Distinct histone modifications denote early stress-induced drug tolerance in cancer
Emran, Abdullah Al, Marzese, Diego M., Menon, Dinoop Ravindran, Stark, Mitchell S., Torrano, Joachim, Hammerlindl, Heinz, Zhang, Gao, Brafford, Patricia, Salomon, Matthew P., Nelson, Nellie, Hammerlindl, Sabrina, Gupta, Deepesh, Mills, Gordon B., Lu, Yiling, Sturm, Richard A., Flaherty, Keith, Hoon, Dave S. B., Gabrielli, Brian, Herlyn, Meenhard and Schaider, Helmut (2017). Distinct histone modifications denote early stress-induced drug tolerance in cancer. Oncotarget, 9 (9), 8206-8222. doi: 10.18632/oncotarget.23654
2017
Journal Article
Keratinocyte sonic hedgehog up-regulation drives the development of giant congenital nevi via paracrine endothelin-1 secretion
Chitsazan, Arash, Ferguson, Blake, Villani, Rehan, Handoko, Herlina Y, Mukhopadhyay, Pamela, Gabrielli, Brian, Mooi, Wolter J, Soyer, H Peter, Lambie, Duncan, Khosrotehrani, Kiarash, Morahan, Grant and Walker, Graeme J (2017). Keratinocyte sonic hedgehog up-regulation drives the development of giant congenital nevi via paracrine endothelin-1 secretion. The Journal of investigative dermatology, 138 (4), 893-902. doi: 10.1016/j.jid.2017.10.032
2017
Journal Article
Inhibition of Aurora A and Aurora B Is Required for the Sensitivity of HPV-Driven Cervical Cancers to Aurora Kinase Inhibitors
Martin, David, Fallaha, Sora, Proctor, Martina, Stevenson, Alexander, Perrin, Lewis, McMillan, Nigel and Gabrielli, Brian (2017). Inhibition of Aurora A and Aurora B Is Required for the Sensitivity of HPV-Driven Cervical Cancers to Aurora Kinase Inhibitors. Molecular Cancer Therapeutics, 16 (9), 1934-1941. doi: 10.1158/1535-7163.MCT-17-0159
2017
Journal Article
Cell cycle-tailored targeting of metastatic melanoma: challenges and opportunities
Haass, Nikolas K. and Gabrielli, Brian (2017). Cell cycle-tailored targeting of metastatic melanoma: challenges and opportunities. Experimental Dermatology, 26 (7), 649-655. doi: 10.1111/exd.13303
2017
Journal Article
Genome-wide overexpression screen identifies genes able to bypass p16-mediated senescence in melanoma
Lee, Won Jae, Skalamera, Dubravka, Dahmer-Heath, Mareike, Shakhbazov, Konstanin, Ranall, Max V., Fox, Carly, Lambie, Duncan, Stevenson, Alexander J., Yaswen, Paul, Gonda, Thomas J. and Gabrielli, Brian (2017). Genome-wide overexpression screen identifies genes able to bypass p16-mediated senescence in melanoma. SLAS Discovery, 22 (3), 298-308. doi: 10.1177/1087057116679592
2017
Conference Publication
Cell cycle-tailored targeting of metastatic melanoma: challenges and opportunities
Haass, N., Spoerri, L., Tonnessen, C. A., Beaumont, K. A., Hill, D. S., Daignault, S. M., Gabrielli, B. and Weninger, W. (2017). Cell cycle-tailored targeting of metastatic melanoma: challenges and opportunities. Australasian College of Dermatologists 50th Annual Scientific Meeting, International Convention Centre, Sydney, NSW Australia, 6-9 May 2017. Richmond, VIC Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/ajd.20_12652
2017
Journal Article
6α-Acetoxyanopterine: a novel structure class of mitotic inhibitor disrupting microtubule dynamics in prostate cancer cells
Levrier, Claire, Sadowski, Martin C., Rockstroh, Anja, Gabrielli, Brian, Kavallaris, Maria, Lehman, Melanie, Davis, Rohan A. and Nelson, Colleen C. (2017). 6α-Acetoxyanopterine: a novel structure class of mitotic inhibitor disrupting microtubule dynamics in prostate cancer cells. Molecular Cancer Therapeutics, 16 (1), 3-15. doi: 10.1158/1535-7163.MCT-16-0325
2017
Journal Article
Topoisomerase II inhibitors and poisons, and the influence of cell cycle checkpoints
D'Arcy, Nicholas and Gabrielli, Brian (2017). Topoisomerase II inhibitors and poisons, and the influence of cell cycle checkpoints. Current Medicinal Chemistry, 24 (15), 1504-1519. doi: 10.2174/0929867323666161205122613
2016
Journal Article
Genome-wide gain-of-function screen for genes that induce epithelial-to-mesenchymal transition in breast cancer
Skalamera, Dubravka, Dahmer-Heath, Mareike, Stevenson, Alexander J., Pinto, Cletus, Shah, Esha T., Daignault, Sheena M., Said, Nur Akmarina B. M., Davis, Melissa, Haass, Nikolas K., Williams, Elizabeth D., Hollier, Brett G., Thompson, Erik W., Gabrielli, Brian and Gonda, Thomas J. (2016). Genome-wide gain-of-function screen for genes that induce epithelial-to-mesenchymal transition in breast cancer. Oncotarget, 7 (38), 61000-61020. doi: 10.18632/oncotarget.11314
2016
Journal Article
Multiparameter analysis of naevi and primary melanomas identifies a subset of naevi with elevated markers of transformation
Fox, Carly, Lambie, Duncan, Wilmott, James S., Pinder, Alex, Pavey, Sandra, Lê Cao, Kim-Anh, Akalin, Taner, Karaarslan, Isil Kilinc, Ozdemir, Fezal, Scolyer, Richard A., Yamada, Miko, Soyer, H. Peter, Schaider, Helmut and Gabrielli, Brian (2016). Multiparameter analysis of naevi and primary melanomas identifies a subset of naevi with elevated markers of transformation. Pigment Cell and Melanoma Research, 29 (4), 444-452. doi: 10.1111/pcmr.12489
2016
Journal Article
A mutation in the Cdon gene potentiates congenital nevus development mediated by NRASQ61K
Chitsazan, Arash, Ferguson, Blake, Ram, Ramesh, Mukhopadhyay, Pamela, Handoko, Herlina Y., Gabrielli, Brian, Soyer, Peter H, Morahan, Grant and Walker, Graeme J. (2016). A mutation in the Cdon gene potentiates congenital nevus development mediated by NRASQ61K. Pigment Cell and Melanoma Research, 29 (4), 459-464. doi: 10.1111/pcmr.12487
2016
Journal Article
Cell cycle phase-specific drug resistance as an escape mechanism of melanoma cells
Beaumont, Kimberley A., Hill, David S., Daignault, Sheena M., Lui, Goldie Y. L., Sharp, Danae M., Gabrielli, Brian, Weninger, Wolfgang and Haass, Nikolas K. (2016). Cell cycle phase-specific drug resistance as an escape mechanism of melanoma cells. Journal of Investigative Dermatology, 136 (7), 1479-1489. doi: 10.1016/j.jid.2016.02.805
2016
Conference Publication
Cell cycle phase-specific drug resistance as an escape mechanism of melanoma cells
Beaumont, K., Hill, D., Daignault, S., Sharp, D., Gabrielli, B., Weninger, W. and Haass, N. (2016). Cell cycle phase-specific drug resistance as an escape mechanism of melanoma cells. Annual Meeting of the Society-for-Investigative-Dermatology (SID), Scottsdale, AZ, United States, 11-14 May 2016. Oxford, United Kingdom: Elsevier. doi: 10.1016/j.jid.2016.02.695
2016
Journal Article
A novel ATM-dependent checkpoint defect distinct from loss of function mutation promotes genomic instability in melanoma
Spoerri, Loredana, Brooks, Kelly, Chia, KeeMing, Grossman, Gavriel, Ellis, Jonathan J., Dahmer-Heath, Mareike, Skalamera, Dubravka, Pavey, Sandra, Burmeister, Bryan and Gabrielli, Brian (2016). A novel ATM-dependent checkpoint defect distinct from loss of function mutation promotes genomic instability in melanoma. Pigment Cell and Melanoma Research, 29 (3), 329-339. doi: 10.1111/pcmr.12466
Funding
Current funding
Past funding
Supervision
Availability
- Professor Brian Gabrielli is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Available projects
-
Identifying the molecular basis for defective checkpoints in melanoma
-
Targeting defective cell cycle responses to ultraviolet radiation and TopoII inhibitors in melanoma
-
Defining the molecular changes in moles underpinning morphological changes detectable by non-invasive imaging techniques to improve their diagnostic and prognostic ability for early stage melanoma
Supervision history
Current supervision
-
Doctor Philosophy
Enhancing immune responses to cancer
Principal Advisor
Other advisors: Honorary Professor John Hooper, Dr Jazmina Gonzalez Cruz
-
Doctor Philosophy
AURKi enhances replication stress targeted by CHK1i in p53 and RB defective cells
Principal Advisor
-
Doctor Philosophy
Assessment of cell cycle phase-dependent immunogenicity of melanoma treated with the proteasome inhibitor bortezomib
Associate Advisor
Other advisors: Professor Nikolas Haass
-
Doctor Philosophy
Modulating phenotypic melanoma heterogeneity and lymphocyte infiltration to improve both targeted and immune therapy
Associate Advisor
Other advisors: Dr Janin Chandra, Professor Nikolas Haass
Completed supervision
-
-
2018
Doctor Philosophy
The Role of Microenvironment in Development of Skin Cancer and Metastasis
Principal Advisor
-
2017
Doctor Philosophy
Mechanisms and markers of CHK1 inhibitors sensitivity in melanoma
Principal Advisor
Other advisors: Professor Nikolas Haass
-
2014
Doctor Philosophy
siRNA screening of the kinome identified Aurora A kinase as a therapeutic target gene in cervical cancer
Principal Advisor
-
2014
Master Philosophy
Identifying molecular changes in naevi driving early stage melanoma
Principal Advisor
Other advisors: Professor Peter Soyer
-
2012
Doctor Philosophy
Investigating the Mode of Action of Histone Deacetylase Inhibiting Agents
Principal Advisor
-
2012
Doctor Philosophy
Selective targeting of the defective decatenaion checkpoint in melanoma
Principal Advisor
-
2011
Doctor Philosophy
The role of MEK1 in progression through G2/M phase of the cell cycle.
Principal Advisor
-
-
2008
Master Philosophy
Investigating The Mechanism Involved In Regulating Ultraviolet Radiation Induced P16 Expression
Principal Advisor
-
2004
Doctor Philosophy
TARGETING CELL CYCLE CHECKPOINTS TO SPECIFICALLY KILL CANCER
Principal Advisor
-
2018
Doctor Philosophy
Distinct Epigenetic Modifications Denote Early Drug Resistance in Cancer
Joint Principal Advisor
Other advisors: Associate Professor Helmut Schaider
-
2018
Doctor Philosophy
Identification of EMI1 overexpression-induced chromosomal instability mechanisms and novel potential therapeutic breast cancer targets
Associate Advisor
-
2016
Doctor Philosophy
Thesis Title: Investigation into the role of the cell surface glycoprotein CDCP1 in high-grade serous ovarian cancer progression
Associate Advisor
Other advisors: Honorary Professor John Hooper
-
2014
Doctor Philosophy
Functional Characterisation of the Cyclin Dependent Kinase-Like 3 Isoforms
Associate Advisor
-
2011
Doctor Philosophy
Protein Arginine Methyltransferase 6 regulates transcription and alternative splicing
Associate Advisor
-
2008
Doctor Philosophy
Functional Characterisation of the Murine Schalafen Proteins: Analysis of Subcellular Localisation and Identification of Binding Partners
Associate Advisor
-
2006
Doctor Philosophy
FUNCTIONAL GENOMICS OF THE PROTEIN KINASES AND PHOTOPHATASES OF MOUSE
Associate Advisor
Other advisors: Associate Professor Rohan Teasdale
Media
Enquiries
Contact Professor Brian Gabrielli directly for media enquiries about:
- Anti-cancer drugs
- Cancer - drugs to prevent
- Cancer - skin
- Cancer - treatment
- Cell cycle
- Drugs - anti-cancer
- Melanoma
- Mitosis
- Radiation - ultraviolet
- Skin cancer
- Sun cancer
- Ultraviolet radiation
- UV rays
Need help?
For help with finding experts, story ideas and media enquiries, contact our Media team: